Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.01 USD | -0.99% | -4.07% | -83.86% |
05-14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
05-10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
Business Summary
Number of employees: 126
Managers
Managers | Title | Age | Since |
---|---|---|---|
Brian Wong
CEO | Chief Executive Officer | 52 | 15-07-31 |
Rodney Young
DFI | Director of Finance/CFO | 61 | 19-12-01 |
Jim Farmer
CTO | Chief Tech/Sci/R&D Officer | - | 22-05-03 |
William Ho
CTO | Chief Tech/Sci/R&D Officer | 58 | 15-04-30 |
Dirk Brockstedt
CTO | Chief Tech/Sci/R&D Officer | 55 | 17-12-31 |
Nipun Davar
CTO | Chief Tech/Sci/R&D Officer | - | 02-12 |
Investor Relations Contact | 63 | - | |
General Counsel | - | 23-05-02 | |
Adnan Rahman
PRN | Corporate Officer/Principal | - | 22-09-27 |
Shari L. Geffon
PRN | Corporate Officer/Principal | - | 22-05-03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 19-12-03 |
William Rieflin
CHM | Chairman | 64 | 15-04-30 |
Wendye Robbins
BRD | Director/Board Member | 63 | 19-10-21 |
Brian Wong
CEO | Chief Executive Officer | 52 | 15-07-31 |
Michael Giordano
BRD | Director/Board Member | 66 | 17-12-31 |
Linda Kozick
BRD | Director/Board Member | 66 | 16-11-30 |
Director/Board Member | 46 | 21-11-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,799,702 | 32,933,918 ( 94.64 %) | 0 | 94.64 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.86% | 140M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- RAPT Stock
- Company RAPT Therapeutics, Inc.